ISRCTN84503991 https://doi.org/10.1186/ISRCTN84503991

The actions of phloridzin on sodium ion transporters and potential difference in nasal airway epithelium.

Submission date 30/09/2005	**Recruitment status** Stopped	[ ] Prospectively registered [ ] Protocol [ ] Statistical analysis plan [ ] Results [ ] Individual participant data [ ] Record updated in last year
Registration date 30/09/2005	**Overall study status** Stopped	
Last Edited 05/04/2011	**Condition category** Respiratory	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Emma Baker

Contact details
St George's Hospital
University of London
Cranmer Terrace
Tooting
London
United Kingdom
SW17 0RE
+44 (0)20 8725 5383
ebaker@sgul.ac.uk

Additional identifiers

Protocol serial number
N0236143719

Study information

Scientific Title

Study objectives
To determine whether nasal application of phloridzin, a sodium-glucose co-transporter (SGLT-1) inhibitor, alters nasal potential difference demonstrating SGLT-1 function.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Wandsworth REC (UK)

Study design
In vivo pharmacological study

Primary study design
Interventional

Study type(s)
Not Specified

Health condition(s) or problem(s) studied
Respiratory: Chronic obstructive pulmonary disease (COPD)

Interventions
Nasal potential difference: between the 'sensing' electrode in contact with the nasal epithelium, and the 'reference' electrode, a butterfly needle inserted under the skin of the forearm, is measured. Phloridzin in Ringer's solution will then be additionally perfused onto the nasal epithelium and any further change in nasal PD recorded. On a second visit a repeat of the above protocol will be carried out with phloridzin followed be amiloride.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
phloridzin

Primary outcome(s)
Changes in the measured nasal potential difference with phloridzin

Key secondary outcome(s))
No secondary outcome measures

Completion date
01/12/2007

Reason abandoned (if study stopped)
Not a clinical trial

Eligibility

Key inclusion criteria
Healthy, non-smoking volunteers with normal nasal mucosa and random plasma glucose <7mmol /l.

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Not Specified

Key exclusion criteria
1. Nasal disease
2. Diabetes mellitus
3. Pregnancy

Date of first enrolment
01/10/2002

Date of final enrolment
01/12/2007

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
St George's Hospital
London
United Kingdom
SW17 0RE

Sponsor information

Organisation
Department of Health

Funder(s)

Funder type
Government

Funder Name
St George's Healthcare NHS Trust (UK)

Funder Name
No External Funding

Funder Name
NHS R&D Support Funding

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration